



## Post Authorisation Assessments

For details of post authorisation assessments prior to 1<sup>st</sup> January 2021,  
please refer to the [EMA](#) website.

### Previcox 57 mg Chewable Tablets for Dogs Vm 04491/5045

22 February 2026	Minor changes to an approved test procedure for the active substance.
10 October 2025	Minor change to an approved test procedure for an intermediate used in the manufacturing process of the active substance.
03 September 2025	Minor Changes: — in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product.
23 November 2024	Deletion of a non-significant specification parameter for the immediate packaging of the finished product.
20 July 2024	One-off alignment of the product information with version 9.0.
18 June 2024	Addition of Boehringer Ingelheim Animal Health UK Ltd as local representative.
18 March 2024	Change in the hold time of the bulk finished product.
24 April 2023	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV).
27 March 2023	Change in dimensions of the container or closure of a non-sterile finished product.
06 December 2022	Minor changes to an approved test procedure for the active substance.
27 September 2022	Change in dimensions of the container or closure of the finished product.
25 February 2022	Changes to the labelling and/or package leaflet.
26 March 2021	Change in the QPPV of an existing pharmacovigilance system as described in the DDPS.